Neil joined our Board in March 2021 as part of the Series B fundraising round, representing Morningside Ventures. He brings over 30 years of experience in biotech and pharma, with multiple compounds progressing into clinical development, including within Oncology, Immune/Inflammation, Pain, CNS and Cardiovascular Disease.
Neil is Research & Operations Director, and Board Member at CellCentric Limited. Neil has extensive experience of managing external collaborations and contracts across Europe, USA and China, including whilst as Director of Chemistry at Piramed, OSI Pharmaceuticals and Glaxo.
Neil obtained his PhD in organic chemistry from University of Nottingham and completed his Post-Doc at Ohio State University, USA.